By Ron Zapata ( May 21, 2008, 12:00 AM EDT) -- Citing European patent law precedents, a U.K. appellate court has reversed a lower court order revoking Merck & Co. Inc.'s patent for male pattern baldness treatment Propecia, finding that Actavis UK Ltd.'s challenge was an "unusual case" in which a change of dosage for a drug was patentable....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.